The goal of this study was to examine whether sub-chronic treatment with the RyR antagonist dantrolene in AD mouse models would normalize ER Ca2+ signaling disruptions, reduce RyR2 expression, stabilize downstream synaptic transmission and plasticity expression, and reduce amyloid pathology. This evidence concerns the gene RYR2 and amyloidosis.